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introduction: Historically, cardiac involvement in AL amyloidosis has been associated with a poor prognosis. We hypothesized that hematopoietic 
stem cell transplantation (HSCT) would result in improved survival in cardiac AL amyloidosis patients.
Methods: 20 consecutive patients with cardiac AL amyloidosis being evaluated for HSCT were studied using biomarkers, bone marrow biopsy, 
echocardiography, cardiac MRI, and cardiac biopsy. Those who underwent HSCT were compared to those who did not. Survival was compared to 
historical controls.
results: 15 of 20 subjects (75%) were able to undergo HSCT. The majority were treated with bortezomib and steroids prior to HSCT. Subjects 
unable to undergo HSCT had higher baseline BNP (median 1640 [IQR 550-1829] vs. 311 [IQR 218-720] pg/ml) and troponin-I (median 
0.21 [IQR 0.05-0.23] vs. 0.04 [IQR 0.02-0.09] ng/ml) compared to those who were able to undergo HSCT, though these differences were not 
statistically significant (P=0.07 and P=0.11, respectively). 13 of 15 HSCT subjects remain alive; they demonstrate improvement in NYHA functional 
class (2.4±0.5 [pre] vs. 1.4±0.5 [post], p<0.0001). Survival of cardiac AL amyloid patients in the current treatment era demonstrated marked 
improvement compared to historical controls (Figure).
conclusions: HSCT is associated with prolonged, recurrence-free survival in patients with cardiac AL amyloidosis. Early diagnosis is essential, and 
cardiac AL amyloidosis should not be considered an untreatable condition.
 
